Queen Sirikit Center for Breast Cancer, King Chulalongkorn Memorial Hospital, Thai Red Cross Society (Chulalongkorn Hospital) has become the world’s first institution to have successfully used immunotherapy to treat a breast cancer patient who is now in complete remission with minimal side effects and uplifted quality of life.
In a study carried out in mice at the University of Chicago, researchers found that lasofoxifene outperformed fulvestrant, the current gold-standard drug, in reducing or preventing primary tumor growth.
Research indicates the rate of cancer recurrence or survival may be no different in older women diagnosed with early breast cancer whether they were treated or untreated.
A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs. The U.S. Food and Drug Administration recently received Oak Ridge National Laboratory’s drug master file for actinium-225 nitrate, which lets pharmaceutical companies reference the document to support applications for their own Ac-225-based drugs without disclosing proprietary information.
Scientists have devised a new way to build nanomaterials that can maintain their structural integrity and functionality in ways relevant to drug delivery. The team developed a class of molecular coatings compatible with biological environments. They used these coating to stabilize wireframed DNA origami cages that can carry an anticancer drug with a slower release of the medicine over time than possible with noncoated counterparts.
Cancer treatment is likely to affect every aspect of a patient’s life — their activities, relationships, eating habits, mental health, physical health and comfort, financial wellbeing. And when financial concerns weigh heavily on an individual who is in treatment for cancer, they can affect the outcome of that treatment. New research from Roswell Park Comprehensive Cancer Center provides the first evidence that a cancer patient’s level of financial worry as they begin treatment predicts how likely it is that their treatment will be successful.
A research partnership formed just last year by Memorial Healthcare System and Florida Atlantic University is already being recognized for quality care, results, and advances in research, and that’s great news for patients fighting cancer in South Florida. The alliance between Memorial’s Cancer Institute and FAU (MCIFAU) has been recognized by the state’s Department of Health as a “Florida Cancer Center of Excellence.” It becomes just the fifth in the state, out of more than 80 competitors, to earn the designation.
Childhood cancer and its treatment can result in cognitive struggles. St. Jude scientists are studying the risk factors.
A pair of research papers from St. Jude Children’s Research Hospital report on a medulloblastoma clinical trial that provides insights to guide treatment and shed light on relapsed disease.
Waldenström macroglobulinemia (WM), a rare form of lymphoma, does not have any known cure and only one FDA-approved treatment making it challenging to treat patients. Researchers at the University of New Hampshire took the novel approach of targeting specific cell proteins that control DNA information using inhibitors, or drugs, that were effective in reducing the growth of the cancer cells and when combined with a third drug were even more successful in killing the WM cancer cells which could lead to more treatment options.
Scientists have figured out a cheaper, more efficient way to conduct a chemical reaction at the heart of many biological processes, which may lead to better ways to create biofuels from plants.
Researchers from Berkeley Lab and Los Alamos National Laboratory have developed new methods for the large-scale production, purification, and use of the radioisotope cerium-134, which could serve as a PET imaging radiotracer for a highly targeted cancer treatment known as alpha-particle therapy.
During the all-virtual 2020 AACC Annual Scientific Meeting & Clinical Lab Expo, leading scientific experts will dive into the groundbreaking advances that are the future of cancer care. One plenary session will focus on the cutting-edge treatment known as T cell therapy, while another will showcase recent discoveries about tumor metabolism that could lead to new, more effective cancer drugs.
Henry Ford Cancer Institute and United Outstanding Physicians (UOP), a physician organization comprising nearly 1,000 independent private practice physicians across Southeast Michigan, have come together to enhance cancer care and make navigating the cancer journey easier for their patients.
Marie Mclaughlin, MSc, from Edinburgh Napier University in Scotland, will present research on human endothelial cells treated with FEC-T, a chemotherapy regimen that combines four drugs (5 fluorouracil, epirubicin, cyclophosphamide and docetaxel). The researchers found that preconditioning the endothelial cells with serum (blood) from people who habitually exercise caused less cell death than samples that were treated with untrained serum (people who exercised less than 75 minutes per week). “Exercise preconditioning can provide protection against these detrimental effects in vitro,” Mclaughlin explained.
Cancer is the second leading cause of death around the world after heart disease. This week, researchers exploring the effects of exercise as a natural preventive tool and noninvasive treatment for cancer will present their work at the American Physiological Society (APS) Integrative Physiology of Exercise conference.
Rutgers researchers have discovered human gene markers that work together to cause metastatic prostate cancer – cancer that spreads beyond the prostate.
The tools will help doctors and patients make better-informed treatment decisions, enhance the care of brain metastases, and enable hospitals to improve the coordination and effectiveness of their interdisciplinary treatment programs.
A new study demonstrates the use of charged nanoscale metal-organic frameworks for generating free radicals using X-rays within tumor tissue to kill cancer cells. The same frameworks can be used for delivering immune signaling molecules to activate the immune response against tumor cells.
A biomedical engineering research team from Tulane University is developing a novel cancer treatment hepatocellular carcinoma, a highly fatal form of liver cancer.
The results of an online questionnaire of 609 breast cancer survivors in the U.S. suggest that nearly half of patients experienced delays in care during the early weeks of the COVID-19 pandemic. The study, by researchers at the University of Illinois Chicago, is published in the journal Breast Cancer Research and Treatment.
Ala Ebaid, MD, completed his fellowship in hematology/oncology at the UNM Cancer Center in June and begins clinical work in August. He’s been in New Mexico for a decade, and he says he doesn’t plan to leave any time soon.
Henry Ford Health System, in partnership with the Detroit Symphony Orchestra (DSO) and Michigan Opera Theatre (MOT), has begun offering virtual musical performances to cancer patients via its music therapy program named for the founding general director of Michigan Opera Theatre, David DiChiera. Through the David DiChiera Music Therapy Program, patients of Henry Ford Cancer Institute will be able to enjoy both live and archived virtual performances from the DSO and MOT at no cost.
A new breast cancer study brings reassuring findings for women with early-stage breast cancer who were forced to delay their cancer operations because of the Coronavirus Disease 2019 (COVID-19) pandemic.
The Rutgers Center for Advanced Biotechnology and Medicine and DuPont Nutrition & Biosciences have announced a new collaboration in the field of microbiome science they hope will improve cancer treatment.
Loyola Medicine recently celebrated its 100th patient to complete cancer treatment with the MRIdian by Viewray radiation therapy system, a novel treatment that utilizes MRI-guided radiation to precisely treat cancerous tumors, typically with fewer treatment sessions and side effects, and better outcomes.
The discovery of the oncogene responsible for glioblastoma could be the brain tumor’s Achilles’ heel, one researcher says.
Weizmann Institute scientists show that bacteria live inside all cancer cells, from brain to breast to bone, and that each type of cancer has its own type of bacteria. Understanding this relationship could help predict treatment effectiveness or lead to ways of using the bacteria to boost treatments.
As the height of the COVID-19 outbreak in New York City and the Tri-State area begins to subside, Memorial Sloan Kettering Cancer Center oncologists are urging patients to schedule cancer screenings and treatments now – as the long-term toll of missed diagnoses and delayed treatments could be devastating for patients and their loved ones across the region and the country.
MD Anderson and Innovent Biologics have announced a strategic collaboration agreement to co-develop Innovent’s anti-PD-1 monoclonal antibody for treating rare cancers in the U.S.
With $3.25 million in new funding from the National Institutes of Health (NIH), a University of Delaware team will examine how the fear of cancer recurrence affects the well-being and relationships of breast cancer patients and their spouses or partners.
For the first time in over a decade, scientists have identified a first-line treatment that significantly improves survival for people with hepatocellular carcinoma, the most common type of liver cancer.
Article title: Angiotensin-(1–7) reduces doxorubicin-induced cardiac dysfunction in male and female Sprague-Dawley rats through antioxidant mechanisms Authors: Omeed Rahimi, Jay Kirby, Jasmina Varagic, Brian Westwood, E. Ann Tallant, Patricia E. Gallagher From the authors: “[Angiotensin]-(1–7) is a clinically safe peptide hormone with cardioprotective…
Researchers who discovered that an engineered cold sore virus could help destroy brain tumors from the inside out have determined a one-two punch might be the key to finish them off. This virotherapy could make a class of investigational cancer drugs more effective, according to investigators at UTHealth.
Research in mice suggests that supplementing the essential nutrient methionine combined with radiation therapy impairs gut function to promote a life-threatening form of radiation toxicity. The study highlights the importance of food and nutrition professionals as part of a cancer treatment team.
Article title: Methionine dietary supplementation potentiates ionizing radiation-induced gastrointestinal syndrome Authors: Isabelle R. Miousse, Laura E. Ewing, Charles M. Skinner, Rupak Pathak, Sarita Garg, Kristy R. Kutanzi, Stepan Melnyk, Martin Hauer-Jensen, Igor Koturbash From the authors: “This study demonstrates that dietary…
Professor Yuval Shaked, head of the Technion Integrated Cancer Center, presents an outline for therapy that will prevent the development of cancer treatment resistance, with suggestions about how the information can be used clinically.
Personalised cancer treatment is one step closer to becoming a reality for more patients, thanks to a Cancer Council Beat Cancer Project grant awarded to University of South Australia researcher Dr Stephanie Reuter Lange to explore how computer-based modelling can optimise cancer treatment and remove the need for expensive clinical trials.
A new study at the University of Georgia has found a way to attack cancer cells that is potentially less harmful to the patient.
Doctors have used focused ultrasound to destroy tumors without invasive surgery for some time. However, the therapeutic ultrasound used in clinics today indiscriminately damages cancer and healthy cells alike. Researchers have now developed a low-intensity ultrasound approach that exploits the properties of tumor cells to target them and provide a safer option. Their findings, reported in Applied Physics Letters, are a new step in oncotripsy, the singling out and killing of cancer cells based on their physical properties.
One in three adults treated for cancer may experience side effects from treatment they wish they had known more about, according to a new survey published in the Journal of Oncology Practice. The national survey of more than 400 U.S. adults, which was sponsored by the American Society for Radiation Oncology (ASTRO), also found that nine in 10 patients felt they made the right treatment decision despite the desire for more information about treatment side effects.
Newly diagnosed prostate cancer patients have multiple standard-of-care treatment options available, but many are not fully informed of their choices. A study led by researchers at The University of Texas MD Anderson Cancer Center found men who seek treatment at a multidisciplinary (MultiD) prostate cancer clinic are more likely to be advised about treatment choices and to receive care that complies with evidence-based treatment guidelines.
MD Anderson, Artios and ShangPharma have announced the in-licensing by Artios of a small-molecule ATR inhibitor program, developed jointly by MD Anderson and ShangPharma.
MD Anderson and Takeda today announced an exclusive license agreement and research agreement to develop CAR NK-cell therapies for the the treatment of B-cell malignancies.
Modern advances in oncology have significantly improved cancer survival rates. However, personalized treatment methods are necessary, since tumors may behave differently for different patients. At the AVS 66th International Symposium and Exhibition, Cristina Canal, a researcher at Universitat Politècnica de Catalunya, will present cold plasmas as a promising tool for minimally invasive cancer therapy. She will discuss the benefits of using plasma jets for cancer therapy, and explain the use of different liquid media, hydrogels and their properties.
New research suggests a vaccine that blocks a digestive hormone may slow the spread of pancreatic cancer, potentially increasing survival rates. The study, published ahead of print in the American Journal of Physiology—Gastrointestinal and Liver Physiology, was chosen as an APSselect article for October.
A new approach may boost the bone repair process for those who have just a 20% chance of a broken bone healing.
Investigational drug with immunotherapy may provide new therapeutic opportunity for patients previously treated for kidney and lung cancer. Pegilodecakin with pembrolizumab and nivolumab shown to be safe in Phase IB study
In companion presentations at the American Society for Therapeutic Radiation Oncology Annual Meeting, doctors from Roswell Park Comprehensive Cancer Center report new evidence that low-dose aspirin and other anti-inflammatories may improve survival in patients with some head/neck and lung cancers.
Henry Ford Cancer Institute is the first-in-Michigan and second-in-the-world to complete an innovative cancer treatment known as Spinal Laser Interstitial Thermal Therapy (SLITT), which destroys cancer cells that are adjacent to the spine without the need for open surgery.